Cell line · CVCL_1259
Papers75
1 to 20 of 75
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Toward Personalized Theranostics: A Modular PET Platform for Antibody-Based Imaging and Therapy. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Inhibition of cyclin-dependent kinases 12/13 using CT7439 as a treatment for colorectal cancer with CDK12 upregulation. | Mol Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Design optimization of antibody-ligand motifs to enhance CAR-T redirection activity against solid tumors. | Cell Rep Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| AXL-SHC1 signaling axis mediates adaptive resistance to HER2-targeted tyrosine kinase inhibitors in HER2-aberrant lung and gastric cancers. | NPJ Precis Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| HER2 Heterogeneous Breast Cancer Models Reveal Novel Therapeutic Targets and Subclonal Dynamics during Evolution to Resistance to HER2-Targeted Therapies. | Cancer Discov | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Payload Diversification Overcomes Resistance and Guides Sequential Antibody-Drug Conjugate Therapy in Breast Cancer. | Clin Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| TPP-45142-an Anti-HER2 T-cell Engager-Designed for Selective HER2-Low Cancer Immunotherapy. | Mol Cancer Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| PM534, a Novel Colchicine Site Tubulin Inhibitor with Broad-Spectrum and Resistance-Overcoming Antitumor Activity. | Mol Cancer Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| In Vivo Auto-tuning of Antibody-Drug Conjugate Delivery to Maximize Efficacy Using High-Avidity, Low-Affinity Antibodies. | Mol Cancer Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| PTEN Loss Promotes PI3Kβ Phosphorylation and EPHA2/SRC/p-PI3KβY962 Complex Assembly to Drive Tumorigenesis. | Cancer Discov | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Machine learning-based development of a cytotoxicity prediction model for NK cell therapy in cancers. | Cell Oncol (Dordr) | 2025 | Its Methods give the RRID and name the line | PubMed | |
| An Fc-Engineered Glycomodified Antibody Supports Proinflammatory Activation of Immune Effector Cells and Restricts Progression of Breast Cancer. | Cancer Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| The Bi-steric, mTORC1-Selective Inhibitor, RMC-5552, in Advanced Solid Tumors: A Phase 1 Trial. | Clin Cancer Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| A Novel B7-H4xCD3 Bispecific T-cell Engager (PF-07260437) Synergizes with Breast Cancer Standard of Care and Immune Checkpoint Therapies. | Mol Cancer Ther | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Novel Metastasis Suppressor PI3KC2β Is Mediated by mTORC1 Signaling in Breast Cancer. | Mol Cancer Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Mucin 5AC Promotes Breast Cancer Brain Metastasis through cMET/CD44v6. | Clin Cancer Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Noninvasive Multicancer Detection Using DNA Hypomethylation of LINE-1 Retrotransposons. | Clin Cancer Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Pyrotinib and trastuzumab combination treatment synergistically overcomes HER2 dependency in HER2-positive breast cancer: insights from the PHILA trial. | EBioMedicine | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Synergistic Effects of PARP Inhibition and Cholesterol Biosynthesis Pathway Modulation. | Cancer Res Commun | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Type I interferon regulation by USP18 is a key vulnerability in cancer. | iScience | 2024 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_1259/papers